三重抗凝药物治疗经皮冠状动脉介入治疗后并发房颤的疗效

Efficacy of Triple Anticoagulant Treatment in Atrial Fibrillation Patients Ater Coronary Stent Implantation

目的分析经皮冠状动脉介入治疗(PCI)后并发房颤的三重抗凝药物的有效性及安全性。方法收集2013年02月至2016年02月于我院心内科行PCI的128例患者,按照术后的治疗方案分为三重抗凝治疗组(实验组,72例)与二重抗凝治疗组(对照组,56例),随访12个月,比较不同治疗方案的安全性及有效性。结果与二重抗凝方案相比三重抗凝方案能显著减低支架内血栓发生率及1年临床终点事件发生率,但三重治疗方案增加总出血发生率。结论PCI术后合并房颤行三重抗凝方案较二重抗凝方案可显著减少支架内血栓发生率及1年临床终点事件发生率,但会增加出血风险。

Objective To analyze the efficacy and safety of triple anticoagulant drugs in atrial fibrillation after percutaneous coronary intervention. Methods From February 2002 to February 2016,128 patients were in our hospital Cardiology Department. According to the postoperative treatment, they were divided into triple anticoagulant treatment group （experimental group, 72 cases）and secondary anticoagulant treatment group （control group,56 cases）. They were followed up for 12 months to compare the safety and efficacy of different treatment regimens. Results Compared with the secondary anticoagulant treatment, the triple anticoagulant treatment significantly reduced the incidence of stent thrombosis and the incidence of 1 year clinical end point, but triple therapy increased the incidence of total bleeding. Conclusion Compared with the secondary anticoagulant treatment, the triple anticoagulant treatment can significantly reduce the incidence of stent thrombosis and the incidence of 1 year clinical end point, but will increase the risk of total bleeding.